Securities code: 600201 securities abbreviation: Jinyu Bio-Technology Co.Ltd(600201) Announcement No.: pro 2022-001 Jinyu Bio-Technology Co.Ltd(600201)
Announcement on the subsidiary’s obtaining the approval document of veterinary drug product approval number
The board of directors and all directors of the company guarantee that there are no false records, misleading statements or major omissions in the contents of this announcement, and bear individual and joint liabilities for the authenticity, accuracy and completeness of its contents. In accordance with the regulations on the administration of veterinary drugs and the measures for the administration of veterinary drug product approval numbers and other relevant provisions, Liaoning Yikang Jinyu Bio-Technology Co.Ltd(600201) Co., Ltd. (hereinafter referred to as “Liaoning Yikang”), a holding subsidiary of Jinyu Bio-Technology Co.Ltd(600201) (hereinafter referred to as “the company”), is approved to produce bivalent inactivated Duck infectious serositis vaccine (type 1 SG4 strain + type 2 zzy7 strain) after examination by the Ministry of agriculture and rural areas, And issue the approval number of veterinary drug products. Details are as follows:
1、 Basic information of veterinary drug product approval number
Veterinary drug product approval No.: veterinary drug Shengzi 060132211
Common name: bivalent inactivated Duck infectious serositis vaccine (type 1 SG4 strain + type 2 zzy7 strain)
Trade name: yayining
Content specification: 10ml / bottle; 20ml / bottle; 40ml / bottle; 100ml / bottle; 250ml / bottle
Validity period of approval: January 18, 2022 to January 17, 2027
2、 Research and development of veterinary drugs
Liaoning Yikang, together with China Agricultural University and other units, jointly carried out the work related to the registration of new veterinary drugs for the above products, and obtained the registration certificate of new veterinary drugs on January 29, 2013. Up to now, the R & D investment of the product is 2.47 million yuan.
The company failed to obtain the specific sales data of bivalent inactivated Duck infectious serositis vaccine (type 1 SG4 strain + type 2 zzy7 strain) in the Chinese market through open channels.
3、 Relevant procedures before the marketing of veterinary drug products
Liaoning Yikang has carried out the application for and approval of product approval number in strict accordance with the regulations on the administration of veterinary drugs and the measures for the administration of veterinary drug product approval number. At present, it has obtained the approval number of the veterinary drug product and meets the conditions for listing and sales.
4、 Impact of veterinary drug products on the company
Duck infectious seroitis is a contagious, acute or chronic septic infectious disease caused by the bacterium leemellitis, which incidence rate is as high as 90%. Because there are many serotypes of Riemerella anatipestifer and there is no cross protection between serotypes, it is difficult to prevent and prevent the disease. The bivalent inactivated Duck infectious serositis vaccine (type 1 SG4 strain + type 2 zzy7 strain) approved by Liaoning Yikang this time adopts the dominant serotype strains prevalent in China. The prepared vaccine has a wide immune spectrum, strong immunogenicity and high safety. There are no side reactions after immunization of ducklings, which can produce good immune effect and ensure the healthy growth of ducks.
The new products with veterinary drug product approval number this time will further enrich the company’s veterinary vaccine product structure, better meet the epidemic prevention needs of customers, and play a positive role in continuously improving the company’s business performance and market competitiveness.
It is hereby announced.
Jinyu Bio-Technology Co.Ltd(600201)
Board of directors
February 9, 2002
